SITE013-0315

completed

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE013 (USA) · Dr. Clarke
consented 2023-03-04

AEs

Serious

Dropout signal

–

Adverse events

severe serious assessed

Grade 4 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-04-13 (study day 23); relationship: Y; serious criteria: life-threatening

moderate assessed

Grade 2 Asthenia — outcome: RECOVERED/RESOLVED; onset 2023-04-13 (study day 23); relationship: not assessed

moderate assessed

Grade 2 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2023-06-05 (study day 76); relationship: N

mild assessed

Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-06-22 (study day 93); relationship: not assessed

moderate assessed

Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-07-19 (study day 120); relationship: not assessed

moderate assessed

Grade 2 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2023-07-22 (study day 123); relationship: not assessed

Data queries

No data queries.